ProtoKinetix, Incorporated

PKTX

US7437221002

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:08:55 2024-04-26 pm EDT			5-day change	1st Jan Change
0.015 ^USD	-3.23%		-11.76%	-21.05%

Mar. 29	ProtoKinetix, Incorporated announced a financing transaction	CI
Mar. 20	ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ProtoKinetix, Incorporated announced that it has received $0.324 million in funding

May 24, 2023

On May 25, 2023, ProtoKinetix, Incorporated closed the transaction. The company amended the terms of the transaction and received $324,000 in the transaction. The company raised $287,000?

in its final tranche.

Latest news about ProtoKinetix, Incorporated

ProtoKinetix, Incorporated announced a financing transaction	Mar. 28	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.11 million in funding	Dec. 25	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-18	CI
ProtoKinetix, Incorporated announced that it has received $0.03 million in funding	23-08-28	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-14	CI
ProtoKinetix, Incorporated announced that it has received $0.324 million in funding	23-05-24	CI
ProtoKinetix, Incorporated announced that it has received $0.324 million in funding	23-05-24	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-02	CI
ProtoKinetix, Incorporated Auditor Raises 'Going Concern' Doubt	23-03-16	CI
ProtoKinetix, Incorporated announced that it has received $0.04 million in funding	23-01-22	CI
ProtoKinetix, Incorporated announced a financing transaction	22-12-29	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.037 million in funding	22-12-29	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.063 million in funding	22-12-08	CI
ProtoKinetix, Incorporated announced a financing transaction	22-12-07	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-31	CI
ProtoKinetix, Incorporated announced that it has received funding	22-10-13	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-29	CI
ProtoKinetix, Incorporated Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants	22-07-20	CI
ProtoKinetix, Incorporated announced a financing transaction	22-07-10	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.2 million in funding	22-07-10	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
ProtoKinetix, Incorporated announced that it has received $0.05 million in funding	22-03-17	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-10	CI
ProtoKinetix, Incorporated Auditor Raises 'Going Concern' Doubt	22-03-09	CI

Chart ProtoKinetix, Incorporated

Duration

Period

More charts

ProtoKinetix, Incorporated is a research and development stage biotechnology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins. The Companyâs anti-aging glycopeptide is for ophthalmology, dermatology, transplant support and biomanufacturing. The commercial applications for AAGPs include various health care solutions. In a clinical setting, AAGP is showing its ability to protect cells from inflammation, repair and replace damaged cells and improve cell survivability over time. The Company has not developed a commercially viable product and has not generated any revenue.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROTOKINETIX, INCORPORATED	-21.05%	5.27M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B